Compare Glenmark Pharma with Procter & Gamble Health - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs PROCTER & GAMBLE HEALTH - Comparison Results

GLENMARK PHARMA     Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

PROCTER & GAMBLE HEALTH 
   Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA PROCTER & GAMBLE HEALTH GLENMARK PHARMA/
PROCTER & GAMBLE HEALTH
 
P/E (TTM) x 10.1 52.2 19.3% View Chart
P/BV x 1.4 4.7 30.4% View Chart
Dividend Yield % 0.7 10.0 7.0%  

Financials

 GLENMARK PHARMA   PROCTER & GAMBLE HEALTH
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-19
PROCTER & GAMBLE HEALTH
Dec-18
GLENMARK PHARMA/
PROCTER & GAMBLE HEALTH
5-Yr Chart
Click to enlarge
High Rs7123,549 20.1%   
Low Rs4841,301 37.2%   
Sales per share (Unadj.) Rs349.6511.4 68.4%  
Earnings per share (Unadj.) Rs32.861.3 53.5%  
Cash flow per share (Unadj.) Rs44.374.0 59.9%  
Dividends per share (Unadj.) Rs2.00440.00 0.5%  
Dividend yield (eoy) %0.318.1 1.8%  
Book value per share (Unadj.) Rs198.6927.8 21.4%  
Shares outstanding (eoy) m282.1716.60 1,699.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.74.7 36.0%   
Avg P/E ratio x18.239.6 46.1%  
P/CF ratio (eoy) x13.532.8 41.1%  
Price / Book Value ratio x3.02.6 115.1%  
Dividend payout %6.1717.9 0.8%   
Avg Mkt Cap Rs m168,62540,257 418.9%   
No. of employees `00012.01.1 1,061.5%   
Total wages/salary Rs m20,5611,313 1,566.3%   
Avg. sales/employee Rs Th8,196.07,486.7 109.5%   
Avg. wages/employee Rs Th1,708.11,157.6 147.6%   
Avg. net profit/employee Rs Th768.5897.2 85.7%   
INCOME DATA
Net Sales Rs m98,6558,490 1,162.0%  
Other income Rs m2,081244 853.4%   
Total revenues Rs m100,7368,734 1,153.4%   
Gross profit Rs m15,8581,482 1,070.3%  
Depreciation Rs m3,259211 1,543.1%   
Interest Rs m3,3460-   
Profit before tax Rs m11,3351,514 748.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1,67266 2,548.5%   
Tax Rs m3,756563 667.8%   
Profit after tax Rs m9,2501,017 909.2%  
Gross profit margin %16.117.5 92.1%  
Effective tax rate %33.137.1 89.2%   
Net profit margin %9.412.0 78.2%  
BALANCE SHEET DATA
Current assets Rs m66,96815,343 436.5%   
Current liabilities Rs m40,2111,960 2,051.4%   
Net working cap to sales %27.1157.6 17.2%  
Current ratio x1.77.8 21.3%  
Inventory Days Days8349 171.0%  
Debtors Days Days8128 285.4%  
Net fixed assets Rs m33,3221,209 2,755.5%   
Share capital Rs m282166 170.0%   
"Free" reserves Rs m55,77015,235 366.1%   
Net worth Rs m56,05215,401 363.9%   
Long term debt Rs m35,7380-   
Total assets Rs m132,88817,595 755.3%  
Interest coverage x4.4NM-  
Debt to equity ratio x0.60-  
Sales to assets ratio x0.70.5 153.9%   
Return on assets %9.55.8 163.9%  
Return on equity %16.56.6 249.8%  
Return on capital %17.810.3 173.7%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m62,9981,636 3,850.1%   
Fx outflow Rs m22,8594,368 523.3%   
Net fx Rs m40,140-2,732 -1,469.4%   
CASH FLOW
From Operations Rs m13,242-1,304 -1,015.6%  
From Investments Rs m-6,99012,697 -55.1%  
From Financial Activity Rs m-7,387-301 2,458.4%  
Net Cashflow Rs m-2,97111,093 -26.8%  

Share Holding

Indian Promoters % 48.3 0.0 -  
Foreign collaborators % 0.0 51.8 -  
Indian inst/Mut Fund % 6.9 18.2 37.9%  
FIIs % 34.4 1.0 3,440.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 29.1 36.1%  
Shareholders   56,727 28,591 198.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   SHASUN PHARMA  CIPLA  TORRENT PHARMA  ALEMBIC LTD  WYETH LTD  

Compare GLENMARK PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 93 Points Higher; Oil & Gas and Realty Stocks Witness Buying(Closing)

Indian share markets traded on a volatile note throughout the day and ended marginally higher. Sectoral indices ended on a mixed note with stocks in the oil & gas sector.

Related Views on News

GLENMARK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of GLENMARK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 53.1% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, GLENMARK PHARMA has posted a net profit of Rs 1 bn (down 53.1% YoY). Sales on the other hand came in at Rs 23 bn (up 7.3% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

PROCTER & GAMBLE HEALTH Announces Quarterly Results (1QFY20); Net Profit Up 34.3% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 441 m (up 34.3% YoY). Sales on the other hand came in at Rs 2 bn (up 6.1% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

PROCTER & GAMBLE HEALTH 2017-18 Annual Report Analysis (Annual Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

Here's an analysis of the annual report of PROCTER & GAMBLE HEALTH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PROCTER & GAMBLE HEALTH. Also includes updates on the valuation of PROCTER & GAMBLE HEALTH.

GLENMARK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 6.6% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 6.6% YoY). Sales on the other hand came in at Rs 26 bn (up 12.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Rebound Riches Could be Yours With These Stocks(Profit Hunter)

Oct 4, 2019

The secret to multibagger is not big businesses, but great managements... Here's how to find them to make the most of once in a decade rebound opportunity.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Oct 16, 2019 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA - SANOFI INDIA COMPARISON

COMPARE GLENMARK PHARMA WITH

MARKET STATS